Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Vildagliptin (Galvus®) is recommended as an option for use within NHS Wales for the treatment of type 2 diabetes mellitus as monotherapy in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. |
|||
|
|||
Medicine details |
|||
| Medicine name | vildagliptin (Galvus®) | ||
| Formulation | 50 mg tablet | ||
| Reference number | 1531 | ||
| Indication | Treatment of type 2 diabetes as monotherapy in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance |
||
| Company | Novartis Pharmaceuticals UK Ltd | ||
| BNF chapter | Endocrine system | ||
| Submission type | Full | ||
| Status | Recommended | ||
| Advice number | 0213 | ||
| NMG meeting date | 09/01/2013 | ||
| AWMSG meeting date | 06/02/2013 | ||
| Ratification by Welsh Government | 18/03/2013 | ||
| Date of issue | 22/03/2013 | ||
| Date of last review | November 2022 | ||
| Further information This appraisal recommendation was reviewed in November 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG’s static list of medicine recommendations |
|||